IgniteData’s system-agnostic electronic data transfer technology, Archer, eliminates the need for researchers to manually transcribe data such as vital signs and labs, domains that typically account for as much as 50% of total data required. Archer’s purpose-built Smart Mapping Engine matches site and sponsor ontologies and normalises complex healthcare data. The solution enables research staff to rapidly transfer existing regulatory-grade data from the EHR to the sponsor’s study database, eliminating data entry errors, and significantly reducing SDV and query resolution time. Scalable by design, Archer is purpose-built for multi-site trials, multiple users, different hospital systems, and complex data collection requirements.
IgniteData’s CEO and Co-founder, Dan Hydes said, “Today, a typical phase 3 oncology study generates an average of 3.6 million data points. More than half of this eSource data already exists in patients’ electronic medical records, yet it is still being painstakingly transcribed into study databases, burdening research staff and creating inefficiencies and delays.
“As pioneers of EHR-to-EDC data interoperability, and in collaboration with MSK’s Innovation Hub, we are proud to lead the drive to solve the clinical trial data challenge and accelerate the pace of clinical trial digital transformation alongside the world’s leading cancer center.”
The MSK Innovation Hub brings together health technology innovators and MSK’s exceptional community of researchers, clinicians, and digital health professionals through a program designed to advance the prevention, treatment, and cure of cancer. The MSK Innovation Hub is targeted at accelerating development of innovative products and businesses that will make a meaningful impact in the lives of people with cancer and caregivers.
“We are excited to collaborate with IgniteData given our shared goal of unlocking the power of EHR data for use in clinical research,” said Joseph Lengfellner, Senior Director, Clinical Research Informatics at MSK. “This collaboration aspires to automate the routine tasks performed by our research teams and quicken the pace of clinical trial execution, driving us toward our ultimate goal of changing how the world treats cancer through research.”
MSK Disclosure: MSK has institutional financial interests related to IgniteData.
About IgniteData
IgniteData is transforming the future of clinical trials through its cloud-based Virtual Research Assistant, Archer. A system-agnostic solution, Archer brings modern interoperability between EHR and key research systems, such as EDC, to provide seamless, secure transfer of clinically-validate data for clinical trials.